PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer

Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy is limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Wang, Kexin, Feng, Xingbo, Wang, Jian, Chu, Yali, Jia, Chunmeng, He, Qingsi, Chen, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578369/
https://www.ncbi.nlm.nih.gov/pubmed/34753906
http://dx.doi.org/10.1038/s41419-021-04352-w
_version_ 1784596238019067904
author Zhang, Xin
Wang, Kexin
Feng, Xingbo
Wang, Jian
Chu, Yali
Jia, Chunmeng
He, Qingsi
Chen, Cheng
author_facet Zhang, Xin
Wang, Kexin
Feng, Xingbo
Wang, Jian
Chu, Yali
Jia, Chunmeng
He, Qingsi
Chen, Cheng
author_sort Zhang, Xin
collection PubMed
description Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy is limited by drug resistance. The findings of the current study showed that HIF1α R282 is methylated by PRMT3, which is necessary for its stabilization and oncogene function. Analysis showed that PRMT3-mediated tumorigenesis is HIF1α methylation-dependent. A novel therapeutic molecule (MPG-peptide) was used to inhibit HIF1α expression. These findings provided information on PRMT3 signaling pathway and HIF1/VEGFA signaling pathway and offer a novel therapeutic strategy for colorectal cancer, mainly for treatment of anti-angiogenesis resistance patients.
format Online
Article
Text
id pubmed-8578369
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85783692021-11-15 PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer Zhang, Xin Wang, Kexin Feng, Xingbo Wang, Jian Chu, Yali Jia, Chunmeng He, Qingsi Chen, Cheng Cell Death Dis Article Abnormal angiogenesis occurs during the growth of solid tumors resulting in increased vascular permeability to fluids and metastatic cancer cells. Anti-angiogenesis therapy for solid tumors is effective in the treatment of cancer patients. However, the efficacy of anti-angiogenesis therapy is limited by drug resistance. The findings of the current study showed that HIF1α R282 is methylated by PRMT3, which is necessary for its stabilization and oncogene function. Analysis showed that PRMT3-mediated tumorigenesis is HIF1α methylation-dependent. A novel therapeutic molecule (MPG-peptide) was used to inhibit HIF1α expression. These findings provided information on PRMT3 signaling pathway and HIF1/VEGFA signaling pathway and offer a novel therapeutic strategy for colorectal cancer, mainly for treatment of anti-angiogenesis resistance patients. Nature Publishing Group UK 2021-11-09 /pmc/articles/PMC8578369/ /pubmed/34753906 http://dx.doi.org/10.1038/s41419-021-04352-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhang, Xin
Wang, Kexin
Feng, Xingbo
Wang, Jian
Chu, Yali
Jia, Chunmeng
He, Qingsi
Chen, Cheng
PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title_full PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title_fullStr PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title_full_unstemmed PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title_short PRMT3 promotes tumorigenesis by methylating and stabilizing HIF1α in colorectal cancer
title_sort prmt3 promotes tumorigenesis by methylating and stabilizing hif1α in colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578369/
https://www.ncbi.nlm.nih.gov/pubmed/34753906
http://dx.doi.org/10.1038/s41419-021-04352-w
work_keys_str_mv AT zhangxin prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT wangkexin prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT fengxingbo prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT wangjian prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT chuyali prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT jiachunmeng prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT heqingsi prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer
AT chencheng prmt3promotestumorigenesisbymethylatingandstabilizinghif1aincolorectalcancer

Ejemplares similares